Earnings Call Intelligence Subscribe
Home › Call Sheets › MDT › Q3'25
Call sheet · Q3'25

Medtronic (MDT)

Q3'25 earnings call · held February 18, 2025 · compared with the Q2'25 call · management-credibility review
9/12
Disclosure score
3 medium, 3 low flags
Financial quality
Bottom line
The sleeper story is PFA becoming a $2B+ revenue engine faster than the market appreciates, with supply constraints now solved and two differentiated platforms. Everyone's focused on the 22% growth acceleration, but the real prize is Martha's casual $2B 'line of sight' comment with Galway factory removing the binding constraint. The renal denervation NCA breakthrough is the obvious headline, but the real binding constraint is implementation bandwidth - they're 'activating accounts' and 'establishing care pathways,' not fighting demand. Most concerning: the surgical distributor excuse sounds exactly like channel stuffing reversal hitting other medtech names. My view changes if they can't deliver the promised Q4 surgical recovery or if CAS revenue in Q4 falls short of the $250M+ needed to hit their $1B annual target.

The 30-second version

  • PFA is quietly becoming a $2B+ business faster than anyone realizes
  • Renal denervation coverage breakthrough masks execution risk
  • Medical Surgical distributor excuse feels like classic channel stuffing reversal

What changed this quarter

MetricQ2'25Q3'25Change
Total Revenue$8.2B (+4.1% YoY)$8.3B (+4.1% YoY)Flat acceleration, in-line
Adjusted EPS$1.26 (+8% CC)$1.39 (+6.9%)+10% QoQ, beat by $0.03
Cardiac Ablation SolutionsMid-single-digit (supply constrained)22% growthMassive acceleration, supply unlocked
Adjusted Gross Margin65.2% (-70 bps YoY)66.6% (+50 bps YoY)+140 bps sequential improvement
Adjusted Operating Margin24.3% (-90 bps YoY)26.2% (+100 bps YoY)+190 bps swing year-over-year
Medical Surgical PortfolioFlat results, Korean headwindsLow-single-digit decline (US distributor impact)200 bps distributor drag, deteriorating
Diabetes11% growth (Q2)10% growthSlight deceleration but double-digit streak continues
Neuromodulation12% growth13% growthAccelerated, market-leading growth
Cranial & Spinal Technologies6% global, 7% US5% global, 8% USUS share gains accelerating
Leadless Pacing (Micra)High-teens growth24% growthAccelerated meaningfully

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full MDT Q3'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.